<DOC>
	<DOCNO>NCT00468039</DOCNO>
	<brief_summary>This study evaluate effect treatment vildagliptin metformin initial combination newly diagnose patient type 2 diabetes high level HbA1c and/or fast plasma glucose .</brief_summary>
	<brief_title>A Sub-study LMF237A2302 Assess Effect 24 Weeks Treatment With Initial Combination Vildagliptin Plus Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female ( nonfertile childbearing potential use medically approve birth control method ) patient type 2 diabetes Diagnosis type 2 diabetes least 4 week prior study entry Body mass index 2240 kg/meter square HbA1c &gt; 11 % and/or FPG &gt; 270 mg/dL Pregnant lactate female History type 1 diabetes Evidence significant diabetic complication Treatment insulin oral antidiabetic agent Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metformin</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>initial combination</keyword>
</DOC>